Award Nominations – Due March 31st

| 2021 News Releases, Corporate News | No Comments
Don't miss out on the opportunity to nominate a colleague or mentor for one of…
Thyroid Volume 30 Issue 6 June 2020

Call for Applications Editor-in-Chief of THYROID®

| 2021 News Releases, Corporate News, Featured, Thyroid Journal | No Comments
Are you interested in serving as the Editor-in-Chief of the world’s leading journal for thyroid-related research?…
ATA Members

Register Today-ATA’s Year in Thyroidology: A Virtual Experience

| 2020 News Releases, Corporate News, Featured, News Releases | No Comments
The inaugural ATA's Year in Thyroidology: A Virtual Experience will be on February 19-20, 2021. …

AbbVie is pleased to introduce the SYNTHROID DELIVERS PROGRAM

| 2020 News Releases, Corporate News, News Releases | No Comments
AbbVie is pleased to introduce the SYNTHROID DELIVERS PROGRAM, a direct-to-patient pharmacy program that offers…

Thyrogen Co-Pay Assistance Program is available to support patient access to Thyrogen.

| 2016 News Releases, Corporate News, Featured | No Comments
Thyrogen Co-Pay Assistance Program is available to support patient access to Thyrogen.  This program helps…

FDA Approves Eisai’s LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

| 2015 News Releases, Corporate News, Thyroid Cancer | No Comments
Eisai is pleased to announce that LENVIMATM (lenvatinib)is now approved for the treatment of locally…

U.S. Prescribing Information for Thyrogen Revised to Include Use of Wider Range of Radioiodine in Patients

| 2014 News Releases, Corporate News, Featured, Hypothyroidism, Radioactive Iodine, Thyroid Cancer | No Comments
Revised label will facilitate use of Thyrogen to greater number of patients for postoperative thyroid…

Return of LEVOXYL® to market

| Corporate News, Goiter, Hypothyroidism | No Comments
February 2014 - Pfizer is pleased to announce that LEVOXYL® (levothyroxine sodium), a prescription medicine…

Phase 3 Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival in Radioiodine-Refractory Differentiated Thyroid Cancer

| Corporate News | No Comments
Woodcliff Lake, NJ, February 2, 2014 – Eisai Inc. announced today that the Phase 3…